#Eisai has agreed a deal to settle #patentinfringement litigation with generic drugmaker #TorrentPharma, preventing it from launching a copycat version of Eisai's #MSD-partnered #cancer drug Lenvima in the US until 2030.

pharmaphorum.com/news/eisai-s...

Torrent-JB Pharma: Strategic Fit, Overpriced Acquisition? Torrent Pharma’s mega JB Chemicals acquisition signals bold ambition. But will its premium bet on scale and diversification pay off or prove costly?

Torrent Pharma’s ₹256.89B JB Chemicals buy is bold—but at 6.7x sales, is it too rich? It may add scale, but risks are real: high price, integration hurdles, and modest rank shift. Strategic or stretched?

Read Dev Chandrasekhar’s article 👇

#TorrentPharma #JBPharma #PharmaPlay #ValuationDebate

Dividend Stocks: Bajaj Auto, Hindustan Zinc, Torrent Pharma, among others to trade ex-dividend next week; Full list - Mint Dividend Stocks: Bajaj Auto, Hindustan Zinc, Torrent Pharma, among others to trade ex-dividend next week; Full list  Mint

Click Subscribe #DividendStocks #BajajAuto #HindustanZinc #TorrentPharma #Investing

Torrent Pharmaceuticals Q4’25 Conference Call Torrent Pharmaceuticals Q4'25 Conference Call #conferencecall #concall #earningscall #torrentpharma #fundamental #fundamentals #future #futureoutlook Here are the highlights from the Q4 FY25 earnings conference call of Torren Pharma: Overall Performance: Strong performance in branded markets, contributing 73% of overall revenues. India business grew by 12% in Q4, while Brazil's constant currency growth was 5%. US generic business grew by 15%, and Germany saw a 2% increase.

Torrent Pharmaceuticals Q4’25 Conference Call

Torrent Pharmaceuticals Q4'25 Conference Call #conferencecall #concall #earningscall #torrentpharma #fundamental #fundamentals #future #futureoutlook Here are the highlights from the Q4 FY25 earnings conference call of Torren Pharma: Overall…